Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease (EUS-SWQ-202601)
EU-ME3 Endoscopic Ultrasound Shear Wave Quantification (EUS-SWQ) for Evaluating Liver Fibrosis and Histopathology in Patients With Chronic Liver Disease
The goal of this clinical study is to learn whether the Olympus EU-ME3 endoscopic ultrasound shear wave quantification (EUS-SWQ) function can accurately diagnose and grade liver fibrosis in patients with chronic liver disease. It will also learn about the safety and measurement success rate of EUS-SWQ.
The main questions it aims to answer are:
How closely do EUS-SWQ measurements match liver fibrosis stages determined by liver biopsy (the reference standard)? Does EUS-SWQ correlate better with liver biopsy results than FibroScan? How safe is EUS-SWQ and how often can successful measurements be obtained? Researchers will compare EUS-SWQ results with liver biopsy pathology (METAVIR F0-F4) and with FibroScan results to evaluate its diagnostic value.
Participants will:
Be adults with chronic liver disease who are scheduled to undergo a clinically indicated liver biopsy Undergo an EUS-SWQ examination as part of the study Have their liver stiffness measured by both EUS-SWQ and FibroScan for comparison Be monitored for any discomfort or adverse events related to the procedures A total of 65 participants will take part in this prospective, single-center, post-market clinical study.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Baiwen Li, MD
- Telefonnummer: 86-21-37798480
- E-post: muzibowen@126.com
Studiesteder
-
-
-
Shanghai, Kina
- Rekruttering
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years and ≤ 80 years.
- Patients with clinical indications scheduled to undergo liver biopsy (EUS-guided) for the evaluation of liver lesions. Chronic liver disease meeting criteria for biopsy includes:Hepatitis B；Fatty liver disease；Autoimmune hepatitis；Other chronic liver diseases of unknown etiology that would benefit from liver biopsy
- Planned to undergo EUS-SWQ and FibroScan examinations prior to biopsy.
- Willing to provide and sign written informed consent.
Exclusion Criteria:
- Patients unable to tolerate endoscopic procedures.
- Patients with contraindications to endoscopy or anesthesia.
- Coagulopathy (platelet count < 50×10⁹/L, PT > upper limit of normal by 3 seconds).
- Patients with severe underlying diseases of the respiratory, cardiovascular, cerebrovascular, digestive, or hematologic systems, as well as those with psychiatric disorders.
- Patients with surgically altered anatomy that precludes adequate EUS imaging of the hepatic parenchyma.
- Patients with imaging findings suggestive of malignant liver tumors.
- Pregnant or lactating women.
- Patients with decompensated cirrhosis (gastrointestinal bleeding, ascites, encephalopathy).
- Patients who refuse to participate in the clinical study.
- Any other conditions deemed inappropriate by the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
One cohort of 65 adult patients with chronic liver disease who are scheduled to undergo clinically i
Sixty-five patients with chronic liver disease who are scheduled to undergo clinically indicated liver biopsy.
Only clinically indicated examinations including EUS-SWQ, FibroScan, and liver biopsy will be performed.
No experimental drug or device intervention is administered in this study.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlation between EUS-SWQ measurements and METAVIR liver fibrosis staging
Tidsramme: 2 weeks after the intervention
|
To assess the correlation between EUS-SWQ measurements and liver fibrosis pathology stages (METAVIR F0-F4) using liver biopsy as the reference standard.
|
2 weeks after the intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison of correlation with liver fibrosis between EUS-SWQ and FibroScan
Tidsramme: At baseline
|
To compare the correlation of EUS-SWQ and FibroScan measurements with histologically confirmed liver fibrosis stages.
|
At baseline
|
|
Safety and measurement success rate of EUS-SWQ
Tidsramme: At baseline
|
To evaluate the safety and technical success rate of EUS-SWQ measurement in patients with chronic liver disease.
|
At baseline
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Baiwen Li, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SH1HY-EUS-SWQ-20260123
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .